Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Sep 5;13(3):257-8.
doi: 10.1016/j.stem.2013.08.009.

Sinister symbiosis: pathological hematopoietic-stromal interactions in CML

Ann Mullally  1 , Benjamin L Ebert
Affiliations
Comment

Sinister symbiosis: pathological hematopoietic-stromal interactions in CML

Ann Mullally et al. Cell Stem Cell. .

Abstract

The impact of myeloid malignancies on the nonhematopoietic components of the bone marrow remains poorly understood. In this issue of Cell Stem Cell, Schepers et al. (2013) describe how malignant myeloid cells alter the endosteal hematopoietic stem cell (HSC) niche, resulting in the expansion of osteoblastic lineage cells that preferentially support malignant HSCs.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Hematopoietic-stromal interactions in chronic myelogenous leukemia (CML)
Osteoblastic lineage cells (OBC) obtained from mice expressing BCR-ABL in the hematopoietic compartment are impaired in their ability to support normal hematopoietic stem cells (HSC) but are supportive of BCR-ABL expressing HSC. Mac-1+ myeloproliferative neoplasm (MPN) cells are markedly expanded and act on multipotent stromal cells (MSC) to promote OBC expansion. OBC are increased in number, and this expansion is associated with collagen deposition in the bone marrow. OBC have an altered molecular signature including reduced expression of HSC retention factors such as Cxcl12, Scf and Lepr. Aberrantly secreted cytokines contribute to paracrine feedback loops. HSC, hematopoietic stem cell; MPN, myeloproliferative neoplasm; MSC, multipotent stromal cell; OBC, osteoblastic lineage cell.
See this image and copyright information in PMC

Comment on

References

    1. Chow A, Lucas D, Hidalgo A, Mendez-Ferrer S, Hashimoto D, Scheiermann C, Battista M, Leboeuf M, Prophete C, van Rooijen N, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med. 2011;208:261–271. - PMC - PubMed
    1. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol. 2013;31:285–316. - PubMed
    1. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798. - PubMed
    1. Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, Dayaram T, Geary K, Green AR, Tenen DG, Huettner CS. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105:324–334. - PubMed
    1. Kvasnicka HM, Thiele J, Bueso-Ramos BR, Hou K, Cortes JE, Kantarjian H, Verstovsek S. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol. 2013;31

MeSH terms